Catalent (CTLT) Tops Q2 EPS by 8c, Revenues Beat; Raises FY21 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Catalent, Inc. Reports Second Quarter Fiscal 2021 Results
February 2, 2021 7:15 AM ESTQ2'21 net revenue of $910.8 million increased 26% as-reported, or 24% in constant currency, compared to Q2'20. Organic, constant currency net revenue grew 17%, compared to Q2'20. Q2'21 net earnings of $88.4 million increased 94%, or 88% in constant currency, compared to Q2'20. Q2'21 Adjusted EBITDA of $223.5 million increased 31% as-reported, or 28% in constant currency, compared to Q2'20. Q2'21 Biologics segment net revenue of $403.9 million increased more than 75%, compared to Q2'20. Increasing guidance to reflect projected net revenue... More
